Hide

FocusBar

FeedbackFeedback
Subscribe to Premium Member
51.11 (1y: +17%)
Market Cap 1.43 B P/E(ttm) 31.00
Enterprise Value 1.29 B P/B 7.60
CYBX- NAS (USA)
Cyberonics, Inc.
  • Currently 1/5
Business Predictability Rank: 1-Star
Back Testing Results:
Average gain of all 1-Star stocks: 1.1% per year.
% of Stocks that are in still loss if held for 10yrs: 45%.
Read more:
What is Predictability Rank?
Performances of real portfolio
Top Ranked Predictable Companies
$51.11
Switch to:

GuruFocus Financial Strength Rank measures how strong a companyย’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry		 vs
history
Cash to Debt 24163.5
CYBX's Cash to Debt is ranked higher than
100% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 1.80 vs. CYBX: 24163.5 )
CYBX' s 10-Year Cash to Debt Range
Min: 0.64   Max: 24163.5
Current: 24163.5
0.64
24163.5
Equity to Asset 0.866
CYBX's Equity to Asset is ranked higher than
93% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.60 vs. CYBX: 0.866 )
CYBX' s 10-Year Equity to Asset Range
Min: -0.12   Max: 0.87
Current: 0.87
-0.12
0.87
Interest Coverage 2238.5
CYBX's Interest Coverage is ranked higher than
78% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 9.60 vs. CYBX: 2238.5 )
CYBX' s 10-Year Interest Coverage Range
Min: 9   Max: No Debt
Current: 2238.5
F-Score: 7
Z-Score: 27.81
M-Score: -2.34
GuruFocus Profitability Rank ranks how profitable a company is and how likely the companyย’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
ย•ย•3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rankย•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry		 vs
history
Operating margin (%) 30.80
CYBX's Operating margin (%) is ranked higher than
97% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 5.40 vs. CYBX: 30.80 )
CYBX' s 10-Year Operating margin (%) Range
Min: -48   Max: 30.8
Current: 30.8
-48
30.8
Net-margin (%) 18.2
CYBX's Net-margin (%) is ranked higher than
93% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 2.50 vs. CYBX: 18.2 )
CYBX' s 10-Year Net-margin (%) Range
Min: -47.9   Max: 46.8
Current: 18.2
-47.9
46.8
ROE (%) 20.2
CYBX's ROE (%) is ranked higher than
97% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. CYBX: 20.2 )
CYBX' s 10-Year ROE (%) Range
Min: -1275.8   Max: 109.5
Current: 20.2
-1275.8
109.5
ROA (%) 17.6
CYBX's ROA (%) is ranked higher than
98% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. CYBX: 17.6 )
CYBX' s 10-Year ROA (%) Range
Min: -40.6   Max: 50.4
Current: 17.6
-40.6
50.4
ROC (Joel Greenblatt) (%) 110.20
CYBX's ROC (Joel Greenblatt) (%) is ranked higher than
96% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 9.60 vs. CYBX: 110.20 )
CYBX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -528.8   Max: 110.2
Current: 110.2
-528.8
110.2
Revenue Growth (%) 11.6
CYBX's Revenue Growth (%) is ranked higher than
94% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. CYBX: 11.6 )
CYBX' s 10-Year Revenue Growth (%) Range
Min: 1.3   Max: 27.4
Current: 11.6
1.3
27.4
EBITDA Growth (%) 21.5
CYBX's EBITDA Growth (%) is ranked higher than
95% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. CYBX: 21.5 )
CYBX' s 10-Year EBITDA Growth (%) Range
Min: -23.1   Max: 31.7
Current: 21.5
-23.1
31.7
EPS Growth (%) -11.2
CYBX's EPS Growth (%) is ranked lower than
58% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. CYBX: -11.2 )
CYBX' s 10-Year EPS Growth (%) Range
Min: -19.4   Max: 20.4
Current: -11.2
-19.4
20.4
ยป CYBX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades
Q2 2012

CYBX Guru Trades in Q2 2012

RS Investment Management 718,242 sh (+20.15%)
Jim Simons 1,211,624 sh (+19.08%)
Steven Cohen 13,497 sh (+14.64%)
John Hussman 997,000 sh (unchged)
Paul Tudor Jones 9,900 sh (-38.89%)
» More
Q3 2012

CYBX Guru Trades in Q3 2012

Jim Simons 1,618,587 sh (+33.59%)
Paul Tudor Jones 12,600 sh (+27.27%)
John Hussman 997,000 sh (unchged)
RS Investment Management 516,100 sh (-28.14%)
Steven Cohen 5,108 sh (-62.15%)
» More
Q4 2012

CYBX Guru Trades in Q4 2012

Joel Greenblatt 6,192 sh (New)
Steven Cohen 21,120 sh (+313.47%)
RS Investment Management 643,373 sh (+24.66%)
Jim Simons 1,846,294 sh (+14.07%)
John Hussman 997,000 sh (unchged)
Paul Tudor Jones 5,200 sh (-58.73%)
» More
Q1 2013

CYBX Guru Trades in Q1 2013

Steven Cohen 111,589 sh (+428.36%)
Paul Tudor Jones 18,400 sh (+253.85%)
Joel Greenblatt 13,195 sh (+113.1%)
Jim Simons 1,955,500 sh (+5.91%)
RS Investment Management 645,847 sh (+0.38%)
John Hussman 898,000 sh (-9.93%)
» More
» Details

Insider Trades

Latest Guru Trades with CYBX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2013-03-31 Add 113.1%0.02%$42.73 - $55.42 $ 51.117%13195
Joel Greenblatt 2012-12-31 New Buy0.02%$44.5 - $53.23 $ 51.112%6192
Joel Greenblatt 2012-03-31 Sold Out 0.05%$32.18 - $39.01 $ 51.1156%0
Joel Greenblatt 2011-12-31 Reduce -24.38%0.02%$26.93 - $34.2 $ 51.1172%12604
Carl Icahn 2011-09-30 Sold Out 0.98%$23.7 - $30 $ 51.1187%0
Joel Greenblatt 2011-09-30 Add 27.85%0.02%$23.7 - $30 $ 51.1187%16667
Joel Greenblatt 2011-06-30 Reduce -23.28%0.04%$24.94 - $35.59 $ 51.1164%13036
John Hussman 2011-03-31 New Buy0.53%$30.66 - $34.96 $ 51.1155%1000000
Joel Greenblatt 2011-03-31 New Buy0.16%$30.66 - $34.96 $ 51.1155%16992
Premium More recent guru trades are included for Premium Members only!!
ยป Financial Charts

Peter Lynch Chart

Ratios

vs
industry		 vs
history
P/E(ttm) 31.00
CYBX's P/E(ttm) is ranked higher than
54% of the 217 Companies
in the Global Medical Devices industry.

( Industry Median: 22.90 vs. CYBX: 31.00 )
CYBX' s 10-Year P/E(ttm) Range
Min: 6.21   Max: 1085.33
Current: 31
6.21
1085.33
P/B 7.60
CYBX's P/B is ranked lower than
65% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. CYBX: 7.60 )
CYBX' s 10-Year P/B Range
Min: 3.42   Max: 180.33
Current: 7.6
3.42
180.33
P/S 5.90
CYBX's P/S is ranked lower than
58% of the 333 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. CYBX: 5.90 )
CYBX' s 10-Year P/S Range
Min: 2.16   Max: 11.24
Current: 5.9
2.16
11.24
PFCF 30.70
CYBX's PFCF is ranked higher than
55% of the 200 Companies
in the Global Medical Devices industry.

( Industry Median: 21.03 vs. CYBX: 30.70 )
CYBX' s 10-Year PFCF Range
Min: 10   Max: 1235.33
Current: 30.7
10
1235.33
EV-to-EBIT 16.4
CYBX's EV-to-EBIT is ranked higher than
71% of the 220 Companies
in the Global Medical Devices industry.

( Industry Median: 18.50 vs. CYBX: 16.4 )
CYBX' s 10-Year EV-to-EBIT Range
Min: 12.2   Max: 309.6
Current: 16.4
12.2
309.6
PEG 0.8
CYBX's PEG is ranked higher than
93% of the 84 Companies
in the Global Medical Devices industry.

( Industry Median: 2.22 vs. CYBX: 0.8 )
CYBX' s 10-Year PEG Range
Min: 0.52   Max: 0.8
Current: 0.8
0.52
0.8
Shiller P/E 39.6
CYBX's Shiller P/E is ranked lower than
100% of the Companies
in the Global Medical Devices industry.

( Industry Median: vs. CYBX: 39.6 )
CYBX' s 10-Year Shiller P/E Range
Min: 33.33   Max: 214.29
Current: 39.6
33.33
214.29

Valuation & Return

vs
industry		 vs
history
Price/Net Cash 20.7
CYBX's Price/Net Cash is ranked higher than
50% of the 90 Companies
in the Global Medical Devices industry.

( Industry Median: 10.50 vs. CYBX: 20.7 )
CYBX' s 10-Year Price/Net Cash Range
Min: 12   Max: 39.1
Current: 20.7
12
39.1
Price/Net Current Asset Value 44.8
CYBX's Price/Net Current Asset Value is ranked lower than
53% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 14.30 vs. CYBX: 44.8 )
CYBX' s 10-Year Price/Net Current Asset Value Range
Min: 16.3   Max: 49.6
Current: 44.8
16.3
49.6
Price/Tangible Book 7.9
CYBX's Price/Tangible Book is ranked lower than
55% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 3.90 vs. CYBX: 7.9 )
CYBX' s 10-Year Price/Tangible Book Range
Min: 5.1   Max: 122.1
Current: 7.9
5.1
122.1
Price/DCF (Projected) 2.2
CYBX's Price/DCF (Projected) is ranked higher than
60% of the 134 Companies
in the Global Medical Devices industry.

( Industry Median: 1.70 vs. CYBX: 2.2 )
CYBX' s 10-Year Price/DCF (Projected) Range
Min: 1.8   Max: 15.1
Current: 2.2
1.8
15.1
Price/Median PS Value 1.2
CYBX's Price/Median PS Value is ranked higher than
52% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 0.90 vs. CYBX: 1.2 )
CYBX' s 10-Year Price/Median PS Value Range
Min: 0.5   Max: 1.8
Current: 1.2
0.5
1.8
Price/Peter Lynch Fair Value 1.2
CYBX's Price/Peter Lynch Fair Value is ranked higher than
85% of the 53 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. CYBX: 1.2 )
CYBX' s 10-Year Price/Peter Lynch Fair Value Range
Min: 1.1   Max: 4
Current: 1.2
1.1
4
Price/Graham Number 3.8
CYBX's Price/Graham Number is ranked lower than
52% of the 195 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. CYBX: 3.8 )
CYBX' s 10-Year Price/Graham Number Range
Min: 1.3   Max: 7
Current: 3.8
1.3
7
Earnings Yield (Greenblatt) 6.10
CYBX's Earnings Yield (Greenblatt) is ranked higher than
82% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. CYBX: 6.10 )
CYBX' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.3   Max: 8.2
Current: 6.1
0.3
8.2
Forward Rate of Return (Yacktman) 52.07
CYBX's Forward Rate of Return (Yacktman) is ranked higher than
99% of the 366 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. CYBX: 52.07 )
CYBX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -7.2   Max: 53
Current: 52.07
-7.2
53

Business Description

Cyberonics, Inc. was incorporated in the state of Delaware in 1987. The Company is a medical device company. It is engaged in the design, development, sales and marketing of implantable medical devices that provide a unique therapy, vagus nerve stimulation therapy (VNS Therapy), for the treatment of refractory epilepsy and treatment-resistant depression. The Company's proprietary VNS Therapy System includes: An implantable pulse generator to provide stimulation to the vagus nerve; A lead that connects the generator to the vagus nerve; Equipment to assist with the implant procedure; Equipment to assist the treating physician with setting the stimulation parameters for each patient; Instruction manuals; and Magnets to temporarily suspend or induce stimulation manually. The VNS Therapy pulse generator and lead are surgically implanted into patients generally during an outpatient procedure. The battery contained in the generator has a finite life, which varies according to the model as well as the stimulation parameters for each patient. At or near the end of the useful life of a battery, a patient may, with the advice of a physician, choose to implant a new generator, which may be done with or without replacing the original lead. The Company sells the VNS Therapy System to hospitals and ambulatory surgery centers ('ASCs') on payment terms that are generally 30 days from the shipment date. The Company's medical devices are subject to regulation by numerous government agencies, including the FDA and comparable foreign agencies.
Company Website
SEC Reports
Industry: Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ
Traded in other countries:JC8.Germany
ยป More Articles for CYBX

Headlines

Articles On GuruFocus.com
comment on CYBX Feb 24 2013 
comment on CYBX Jan 26 2013 
Cyberonics Inc. (CYBX) President & CEO Daniel Jeffrey Moore sells 44,700 Shares Jan 13 2011 
Cyberonics Inc. (CYBX) VP Finance & CFO Gregory H Browne sells 10,000 Shares Jan 12 2011 
Cyberonics Inc. (CYBX) VP Finance & CFO Gregory H Browne sells 5,000 Shares Dec 08 2010 
Cyberonics Inc. Reports Operating Results (10-Q) Nov 22 2010 
Cyberonics Inc. Reports Operating Results (10-Q) Aug 26 2010 
Cyberonics Inc. Reports Operating Results (10-K) Jun 17 2010 
Cyberonics Inc. Reports Operating Results (10-Q) Feb 18 2010 
Cyberonics Inc. Reports Operating Results (10-Q) Nov 19 2009 

Personalized Checklist





Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK